Copaxone 40

Morgan Stanley’s David Risinger maintained an Overweight rating on Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA), with a price target of $71. U.S. Patent Decision Unpredictable Although both the analyst’s and the consensus expectations are for the U.S. Copaxone 3TW patents...